MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has launched its lead commercial software Intox AI for validation and testing of intoxication and fatigue. Intox AI enables new analytical capabilities to...
Tempest Therapeutics (NASDAQ: TPST) has appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its board of directors (BoD), effective June 4, 2026. Mr. Richey and Dr. Yee collectively bring decades...
TelyRx Holdings (TSX: TELY; OTCQX: TELYF) has announced that its subordinate voting shares will commence trading on the OTCQX Best Market (OTCQX), the premier tier of the OTC Markets Group in the U.S., under the symbol...
Cocrystal Pharma (NASDAQ: COCP) has appointed biopharma industry leader James Sapirstein as chief executive officer (CEO), effective immediately. According to Cocrystal, Mr. Sapirstein will also be appointed to its...
VolitionRx (NYSE AMERICAN: VNRX) has announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology in triaging and monitoring patients who are suspected of having contracted...
ENvue Medical (NASDAQ: FEED) has announced that Critical Care Nurse, the official journal of the American Association of Critical-Care Nurses (AACN), has published an independent, peer-reviewed study showing significant...
Closely held Siloton is developing a patented miniaturized medical imaging platform that combines photonic chips with optical coherence tomography (OCT) to detect and monitor a range of prevalent ophthalmic diseases...
Senzime (STO: SEZI; OTCQX: SNZZF) has announced the launch of its TetraSens electromyography (EMG) sensor for use with the TetraGraph Train-of-Four monitoring system for anesthesia monitoring. According to Senzime, the...
Closely held Cercare Medical and Siemens Healthineers (FSE: SHL) have announced a global collaboration to accelerate the adoption of Cone-Beam CT Perfusion (CBCT-P) in acute stroke care, leveraging its capability to...
BioXcel Therapeutics (NASDAQ: BTAI) has announced new positive Phase 3 SERENITY At-Home data for BXCL501 in agitation associated with bipolar disorders or schizophrenia, to be presented this week at the 2026 American...